Observers Fear Funding Practices May Spell The Death Of Innovative Grant Proposals

Point Grants:NIGMS' Marvin Cassman agrees that risky proposals don't get funded. The traditional, romantic notion of scientific research is of a glorious, serendipitous journey into the unknown. But this ideal is belied, in the perception of many scientists, by the apparent reality that much of what gets funded these days is less exploratory and more predictable_cloning and sequencing a gene, for example. While not denying the importance of such predictable studies, the scientific community s

| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

The traditional, romantic notion of scientific research is of a glorious, serendipitous journey into the unknown. But this ideal is belied, in the perception of many scientists, by the apparent reality that much of what gets funded these days is less exploratory and more predictable_cloning and sequencing a gene, for example.

While not denying the importance of such predictable studies, the scientific community shares a nearly universal conviction that proposals for risky, innovative research stand very little chance of being funded by federal granting agencies. Grant administrators themselves acknowledge that unconventional ideas or those with a short or disputed track record rarely make the cut.

"Controversial areas will not do as well as applications where there is broad consensus," states Marvin Cassman, acting director of the National Institute of General Medical Sciences (NIGMS). "Given the degree of difficulty in funding these days, some applications [in areas] where there is [scientific] ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

  • Billy Goodman

    This person does not yet have a bio.

Published In

Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo
Sapio Sciences logo

Sapio Sciences Introduces Biorepository Management Solution